Russian Supplement Regulation Demands Careful Navigation
This article was originally published in The Tan Sheet
Executive Summary
In a guest commentary, Alexey Petrenko, a regulatory consultant in Eastern Europe, notes that Russia has emerged as a driver of growth in the global supplement market with double-digit compound annual growth over the past 10 years. But given the regulatory landscape, firms should be vigilant in staying abreast of how authorities are interpreting rules and where they are targeting their efforts.
You may also be interested in...
Valeant’s OTC Pickups Emphasize Specialty Segments, Growth Markets
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.